Abstract:Objective: To investigate the DNMT3A R882 mutation in children with acute myeloid leukemia (AML) and its effect on prognosis. Methods: A total of 148 children with AML treated in our hospital (March 2017 and March 2020) were selected for this study. According to the detection results of DNMT3A R882 mutations, the children were assigned into the mutation group (n = 20) and the non-mutation group (n = 128). The correlation of DNMT3A R882 mutation and non-mutation with other gene mutations in the children was observed; the clinical characteristics and cellular immune phenotype, as well as clinical remission rate, recurrence rate (RR) and overall survival (OS) after treatment were compared. Results: By genetic mutation detection, there were 20 cases (13.51%) with DNMT3A R882 mutation and 128 cases (86.49%) without DNMT3A R882 mutation among the children with 148 AML; the DNMT3A and NPM1 mutations were similar in the two groups (P > 0.05). The difference in the CEBPA mutation, FLT3-ITD mutation, and double mutation of FLT3-ITD and CEBPA was statistically significant between the two groups (P < 0.05). The white blood cell count, hemoglobin, and platelet levels in the DNMT3A R882 mutant group were higher than those in the non-mutation group (P < 0.05). The positive detection rates of CD15 (80.00%) and CD33 (75.00%) were increased in the DNMT3A R882 mutation group compared with the non-mutation group (35.16% vs 36.72%), whereas the detection rate of CD34 (7.50%) was reduced (P < 0.05). After treatment, the RR (90%) was significantly higher in the DNMT3A R882 mutation group than in the non-mutation group (13.28%), but the OS and disease-free survival (DFS) in the DNMT3A R882 mutation group were shorter than those in the non-mutation group (P < 0.05). The survival time in the DNMT3A R882 mutation group was shorter than that in the non-mutation group (chi(2) = 2.720, P = 0.032). WBC, PLT, HIB, CD15, CD34, and CD33 were independent risk factors for AML in the mutation group. Conclusion: DNMT3A R882 mutation is a common expression method of DNMT3A in AML. Children with DNMT3A R882 mutations have a higher white blood cell count, hemoglobin, and platelet levels. The cellular immune phenotypes CD15, CD33 are highly expressed, CD34 is lowly expressed, and DNMT3A R882 mutation may be associated with a poor prognosis in AML patients.

Influence of DNMT3A R882 Mutations on AML Prognosis Determined by the Allele Ratio in Chinese Patients

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.

DNMT3A R882 mutation in children with acute myeloid leukemia and its role in prognosis

FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

Clinical characteristics of acute myeloid leukemia with DNMT3A R882 mutation

Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.

Association Between Dnmt3a Mutations And Prognosis Of Adults With De Novo Acute Myeloid Leukemia: A Systematic Review And Meta-Analysis

FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation

DNMT3A mutations and clinical features in Chinese patients with acute myeloid leukemia

DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation

[Analysis of DNMT3a gene mutations in acute myelogenous leukemia]

The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia

[Effects of DNMT3A Gene Mutations on Prognosis of Patients with Acute Myeloid Leukemia: a Meta-Analysis].

Clinical Features and MicroRNA Expression Patterns Between AML Patients with DNMT3A R882 and Frameshift Mutations

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Correlation of the Poor Prognosis of Acute Myeloid Leukemia Withflt3-Itd Anddnmt3a Mutations

DNMT3A Mutation Analysis in Adult Patients with Acute Lymphoblastic Leukemia

[Prognostic Value of DTA Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia]

P3.02-080 DNMT3A Defines a Unique Molecular Class of Chinese Non-Small Cell Lung Cancer Patients